title: Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed.
authors.forename: A S
authors.initials: AS
authors.lastname: Belgi
authors.forename: M
authors.initials: M
authors.lastname: Azeez
authors.forename: C
authors.initials: C
authors.lastname: Hoyle
authors.forename: R E A
authors.initials: RE
authors.lastname: Williams
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008775:Methylprednisolone / Q000008:administration & dosage; D010392:Pemphigus / Q000188:drug therapy*; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D008775:Methylprednisolone